SCM
SYRE icon

Sio Capital Management’s Spyre Therapeutics SYRE Stock Holding History

Sio Capital Management’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-120,198
Closed -$871K – 57
2023
Q1 		$871K Hold
120,198
– – 0.43% 33
2022
Q4 		$1.35M Sell
120,198
-66,543
-36% -$1.2M 0.5% 28
2022
Q3 		$2.46M Hold
186,741
– – 0.78% 22
2022
Q2 		$2.36M Buy
186,741
+151,897
+436% +$5.32M 0.89% 31
2022
Q1 		$2M Buy
34,844
+14,904
+75% +$1.25M 0.66% 36
2021
Q4 		$2.37M Buy
19,940
+2,100
+12% +$331K 0.71% 39
2021
Q3 		$3.55M Buy
17,840
+1,734
+11% +$303K 1.13% 29
2021
Q2 		$2.8M Hold
16,106
– – 0.7% 45
2021
Q1 		$3.19M Buy
16,106
+8,462
+111% +$1.62M 0.65% 50
2020
Q4 		$1.5M Sell
7,644
-800
-9% -$166K 0.31% 74
2020
Q3 		$1.5M Hold
8,444
– – 0.3% 67
2020
Q2 		$1.95M Buy
+8,444
New +$1.61M 0.57% 50
2017
Q4 		– Sell
-5,183
Closed -$639K – 62
2017
Q3 		$639K Hold
5,183
– – 0.33% 46
2017
Q2 		$499K Sell
5,183
-1,613
-24% -$223K 0.24% 54
2017
Q1 		$1.27M Sell
6,796
-743
-10% -$105K 0.71% 34
2016
Q4 		$820K Buy
7,539
+1,366
+22% +$199K 0.48% 40
2016
Q3 		$989K Buy
6,173
+498
+9% +$69.3K 0.68% 30
2016
Q2 		$690K Buy
+5,675
New +$1.09M 0.35% 38

Other funds holding SYRE

FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Sio Capital Management's SYRE Position: Q2 2023 in Review

Sio Capital Management sold out of Spyre Therapeutics (SYRE) in Q2 2023, closing a stake of 120,198 shares — an estimated $871K sold.

Sio Capital Management first reported a position in SYRE in Q2 2016 and held it in 18 quarters. The position peaked at $3.55M in Q3 2021. 43 funds tracked by Wall St. Rank hold SYRE as of Q2 2023.

  • Sio Capital Management reported no remaining Spyre Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Sio Capital Management sold 120,198 Spyre Therapeutics shares in Q2 2023, an estimated $871K.
  • Sio Capital Management first reported a position in Spyre Therapeutics in Q2 2016 and held it in 18 quarters.
  • Sio Capital Management's Spyre Therapeutics position peaked at $3.55M in Q3 2021.
  • 43 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q2 2023.

Based on Sio Capital Management's 13F filing for Q2 2023, filed 14 Aug 2023.